Needham & Company Reiterates Apellis Pharmaceuticals (APLS) at Buy, $70 PT, "Data Bode Well for Approval in GA"
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
